HIV infection of the central nervous system leads to HIV-associated dementia (HAD) in a substantial subset of infected individuals. The pathogenesis of neuronal dysfunction in HAD is not well understood, but previous studies have demonstrated evidence for activation of apoptotic pathways. The tumor suppressor transcription factor p53 is an apical mediator of neuronal apoptosis following a variety of injurious stimuli. To determine whether p53 participates in HAD, we exposed cerebrocortical cultures from wild-type and p53 deficient mice to the neurotoxic HIV envelope protein gp120. Using neuron/microglia co-culture of mixed p53 genotype, we observed that both neurons and microglia require p53 for gp120 induced neuronal apoptosis. Additionally, accumulation of p53 protein in neurons was recently reported in postmortem cortical tissue from a small group of HAD patients. Using a much larger cohort of HAD cases, we extend this finding and report that p53 protein also increases in non-neuronal cells, including microglia. Taken together these findings demonstrate a novel role for p53 in the microglial response to gp120. Additionally, these findings, in conjunction with a recent report that monocytes expressing HIV-Tat also secrete neurotoxins that promote p53 activation, suggest that distinct HIV proteins may converge on the p53 pathway to promote neurotoxicity.
cross the threshold for apoptosis (sub-apoptotic neurodegeneration) is the pathologic substrate for neurological dysfunction in HAD. In several chronic neurodegenerative diseases, the molecular mediators of apoptosis may also participate in sub-apoptotic forms of neurodegeneration. For example, neuropathology specimens from patients with fronto-temporal dementia, Cruetzfeld-Jacob disease, or HAD demonstrate caspase-3 activation in a large population of neurons that do not appear apoptotic (6, 9, 10) . Furthermore, caspase enzyme inhibition prevents dendrite degeneration (6) in a transgenic mouse model of HAD (11) . These findings support the hypothesis that the signal transduction pathways and enzymatic mediators of apoptosis may also promote neuronal dysfunction through promotion of sub-apoptotic neurodegeneration.
Several lines of evidence suggest p53, a pro-apoptotic transcription factor, is one candidate mediator of HIV-induced neuronal injury. Peripheral blood mononuclear cells and lymph node syncytia from HIV patients demonstrate accumulation of phosphorylated p53 (12) . CD4 expressing HeLa cells exposed to gp120 envelope protein demonstrate activation of p53-dependent transcription and undergo p53-dependent apoptosis (12) (13) (14) . Accumulation of p53 protein is also observed in CNS tissue from monkeys with simian immunodeficiency virus encephalitis SIVE (15) , and evidence for p53 accumulation in neurons of HAD patients has recently been reported (16) . Additionally, p53 participates in neuronal apoptosis mediated by excitotoxins (17, 18) , an important component of the neurotoxic milieu observed in HAD and HAD models (1) . Finally, p53-deficient mice are resistant to dendrite degeneration in a mouse model of cerebellar Purkinje cell degeneration where apoptosis is not observed (19) , which supports a role for p53 in sub-apoptotic forms of neurodegeneration. Taken together, these studies suggest a role for p53 in the HIV-infected CNS and support the hypothesis that p53 may participate in sub-apoptotic degeneration.
To investigate the hypothesis that p53 is a mediator of neuronal injury in HAD, we used an in vitro model of HAD, primary murine cerebrocortical cultures exposed to the HIV coat protein gp120. Neurotoxic concentrations of gp120 promoted p53 accumulation in these cultures and cultures from p53-deficient mice were resistant to gp120 toxicity. Through use of neuronmicroglia co-cultures of mixed genotype we observed that both neurons and microglia require p53 for gp120-induced neuronal apoptosis. Microglia from p53-deficient mice are distinct from wild-type microglia in their surface expression of CCR5 and their resistance to gp120-induced caspase-3 activation, which suggests that p53 may be required for microglia to respond to gp120 in a manner that generates a neurotoxic milieu. Additionally, we localized p53 content by immunohistochemistry in CNS tissue from HAD patients. A striking degree of p53 accumulation was observed not only in neurons but also in microglia and astrocytes in cortical tissue sections from HAD cases. The experiments reported here reveal a novel role for p53 in the regulation of the microglial response to gp120 and support the hypothesis that p53 activation participates in the pathogenesis of HAD.
MATERIALS AND METHODS

Human tissue
Samples of frontal cortex from human subjects in prospective studies on HIV-related neurologic disease collected at the time of autopsy and fixed in formalin were obtained from the National NeuroAIDS Tissue Consortium (NNTC) with institutional approval from the University of Washington (IRB protocol # 02-0429). All selected cases and controls were in hospital deaths with post-mortem intervals of 3-18 h. Cases with evidence of CNS opportunistic infections or CNS pathology unrelated to HIV encephalitis or HAD on the initial neuropathology autopsy report were excluded. Assignment to the HAD group was made for cases so designated by the NNTC or if the autopsy report listed HAD as a premorbid diagnosis. Paraffin-embedded tissue was sectioned, mounted on slides, deparaffinized in citrulline-based solvent and rehydrated prior to immunolabeling. Sections immunolabeled for p53 alone were counter-stained with hematoxylin. Slides were evaluated and scored for p53 immunoreactivity by a neuropathologist (TJM) who was unaware of the premorbid diagnosis. Adjacent sections were evaluated for general pathology, and cases with signs of obvious ischemic change were excluded from the analysis.
Cell culture
Cortical tissue from postnatal Day 0 (P0) mice was dissected and cut into small pieces (~1 mm 3 ). Tissue pieces were incubated with 0.125% trypsin at 37°C for 25 min, before 1 mg/ml soybean trypsin inhibitor was added. The cells were dissociated by trituration in Neurobasal TM (Gibco, Great Island, NY) media containing 10 mM HEPES and 100 µg/ml DNase I and were counted on a hemocytometer. To obtain mixed cerebrocortical cultures, cells were plated at a density of 2.2 × 10 3 /mm 2 on poly-D-lysine coated glass coverslips (for microscopy) or coated tissue culture plastic (for protein chemistry) in DMEM/F12 (Gibco) supplemented with 2 mM glutamine, 10 mM HEPES (N-(2-hydroxyethyl)piperazine-N′-ethanesulfonic acid), 10% heat-inactivated horse serum, and 2% B27 supplement for 14 days. Pure neuron cultures were grown by methods described previously (20) . Using these culture conditions, pure neuron cultures were used in coculture experiments after 7 days in vitro because general neuronal survival begins to decline after this point. Microglia and astrocytes were obtained from P3-4 mice by using established techniques (21) . For co-culture experiments, microglia are dissociated from the astrocyte monolayer by gentle tapping and were seeded on pure neurons at a density of ~30 cells/mm 2 (3000 microglia per well).
Caspase activity assays
After HIV/gp120 exposure, cultures were lysed in caspase assay lysis buffer (1% sucrose, 0.1% CHAPS, 100 mM HEPES, 2 mM dithiothreitol, pH 7.4). Lysates were assayed for caspase-3 activity as described previously (6) . Arbitrary fluorescence units were normalized by using a free AFC standard curve to give pMole AFC released per milligram of total protein in each lysate.
Cellular labeling
Human tissue sections were subjected to microwave antigen retrieval in 10 mM sodium citrate at pH 6.0. A monoclonal antibody against human p53 (DAKO, Carpinteria, CA) was used and signal amplification was obtained by using the ABC Elite detection kit (Vector Labs, Burlingame, CA). To identify the non-neuronal cell types with increased nuclear p53 protein, double-labeling was carried out with rabbit anti-GFAP (DAKO) or a monoclonal anti-CD68 antibody (DAKO, KP1 clone). Primary cultured neurons, microglia, or mixed cerebrocortical cultures were pretreated with Fc block (Vector) and labeled for activated caspase-3 by using a polyclonal antiserum that recognizes only activated caspase-3 (Cell Signaling Technologies, Beverly, MA). Neurons and microglia in mixed culture were specifically identified by using the monoclonal antibody NeuN (ChemiconTemecula, CA) and the murine microglial specific tomato lectin, lycopersicon esculentum (Vector) after pretreatment with the mouse-anti-mouse blocking agent and secondarily labeled with a biotinylated anti-mouse IgG specifically generated to prevent non-specific binding to surface IgG on mouse microglia (Vector). Apoptotic cells were identified by condensed nuclear morphology in cells labeled with bisbenzamide. This method was developed by double-labeling cultures with bisbenzamide and the Dead End TM fluorescent TUNEL system (Promega, Madison, WI). Observers were trained to reliably identify TUNELlabeled cells by using only the nuclear morphology information. Observers with proven ability to generate apoptotic cell counts based on nuclear morphology that closely approximated those obtained by using TUNEL performed all further apoptosis counts. For flow cytometry, isolated primary mouse microglia were labeled with phycoerythrin conjugated rat monoclonal antibodies against mouse CD4, CXCR4, or CCR5 and FITC-conjugated CD11b (BD-PharMingen, San Diego, CA) at 4°C. The number of CD11b+ cells with surface expression of these receptors determined on a FACScan (Becton Dickenson, Franklin Lakes, NJ). Live microscopy of neuronmicroglia co-cultures was performed at 4°C to prevent phagocytosis of the primary antibody and was visualized by secondary label with AlexaFlour TM -594 conjugated anti-rat IgG (Molecular Probes, Eugene, OR). Appropriate isotype control antibodies were used for all experiments employing immunolabeling techniques.
Calcium imaging
Cultured microglia were plated on glass coverslips and loaded with calcium indicator Fura-2 according to methods described previously (21) . ATP (100 µM) or thrombin (10 U/ml) was added and the calcium concentration measured at 2 s intervals.
Western blot
Cells were lysed in a protein extraction buffer containing 50 mM Tris-HCl; 150 mM NaCl; 5 mM EDTA, pH 7.4; 1% Na deoxycolate; 0.1% SDS; 1% Triton X-100; 1 mM PMSF; 7 µg/ml pepstatin; 5 µg/ml aprotinin; 5 µg/ml leupeptin; and 160 mM sodium orthovanadate, separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), transferred to 0.2 µm nitrocellulose membrane (Bio-Rad, Hercules, CA), and probed with p53 (Oncogen-Ab3) monoclonal antibody. Proteins were visualized with horseradish peroxidase-coupled antibodies (Santa Cruz Biotechnologies, Santa Cruz, CA) and Enhanced Chemiluminescence (Pierce, Rockford, IL).
Statistical analysis
Statistical analysis was performed by using SPSS or StatView TM software with assistance from the biostatistics consulting services at the University of Washington. Dichotomized data were analyzed by using a two by two contingency table and Fisher's exact test. Student's t-test was used when comparing one continuous variable in two groups. One-way analysis of variance (ANOVA) with post hoc comparison by Fisher's LSD was performed on all experiments where >2 experimental groups were included.
RESULTS
An in vitro model of HAD involves p53
To determine whether p53 participates in the pathogenesis of HAD, we developed a novel murine culture model of HIV-induced neurodegeneration. Cerebrocortical tissue obtained from newborn (P0) mice was dissociated, and cells were plated in medium with B27 supplement to ensure survival of postnatal neurons and 10% horse serum to support non-neuronal cells. After 14 days in vitro, the resulting mixed cerebrocortical cultures contained microtubule-associated protein-2 (MAP-2) immunoreactive neurons, and glial fibrillary acidic protein (GFAP) immunoreactive astrocytes (Fig. 1A) in proportions similar to those reported in mixed cerebrocortical cultures obtained from embryonic rats (6, 22) . These cultures also contained microglia identified by labeling with the microglial specific tomato lectin, lycopersicon esculentum (Fig. 1A) . Microglia in this culture system demonstrated both amoeboid and ramified morphologies described in previous studies (23, 24) . Previous studies documented that mixed cerebrocortical cultures from embryonic rats treated with the HIV-1 viral coat protein gp120 (recombinant gp120 SF2 , NIH AIDS reagent program) at a low concentration (200 PM) for 24 h resulted in increased neuronal apoptosis without concurrent astrocyte or microglia apoptosis (6, 22) . Based on this previous work, mixed cerebrocortical cultures from P0 mice were treated with 200pM gp120 or vehicle control for 24 h. At the end of this exposure period, these cultures develop an increase in the portion of neurons demonstrating an apoptotic nuclear morphology (Fig. 1B ) and elevated caspase-3 enzymatic activity (Fig. 1C) . No increase in apoptosis was observed when gp120 was heat-inactivated at 95°C for 10 min (data not shown). These findings reproduce previously reported effects of recombinant gp120 on embryonic rat mixed cerebrocortical cultures (6, 22) , demonstrating that mixed cerebrocortical cultures obtained from postnatal mice can be used to study the neurotoxicity of HIV/gp120 in vitro. Concurrent with the activation of caspase-3 and induction of neuronal apoptosis, exposure to HIV/gp120 produced a robust increase in p53 protein level in this culture system (Fig. 1D ). This finding suggests that exposure to gp120 results in p53 protein stabilization in cultured CNS cells.
Previous studies have shown that neurons deficient in p53 are resistant to apoptosis induced by excitotoxins (18, 20) , nitric oxide (NO) donors (25) , and DNA damaging agents (26, 27) . To determine whether p53 expression is required for gp120-neurotoxicity, mixed cerebrocortical cultures were prepared from p53-deficient (p53 -/-) mice. To control for the possible effect of strain variation, all control cultures were prepared from a p53 containing strain (p53 +/+ ) derived from the original F1 heterozygotes used in the generation of p53 −/− mice (28). After 14 days in vitro, the portion of cells with a neuronal phenotype in p53 −/− cultures was similar to that observed in cultures prepared from p53 +/+ animals, while a smaller portion of cells contained GFAP immunoreactivity (Fig. 2A) . However, the total number of microglia present in p53 −/− cultures after 14 days in vitro was dramatically increased compared with that observed in p53 +/+ cultures (Fig. 2B ). Because neurotoxicity induced by gp120 requires activated microglia (22) , increased gp120-neurotoxicity might be expected in p53 −/− cultures. Despite the increased number of microglia, neurons in p53 −/− cultures were protected from gp120-induced apoptosis (Fig. 2C ).
To determine whether neurons require p53 for gp120-neurotoxicity, we examined neuronmicroglia co-cultures of mixed genotype 24 h after the addition of gp120. We generated relatively pure neuron, microglia, and astrocyte cultures from p53 +/+ and p53 −/− mice. The addition of 200pM gp120 for 24 h to pure astrocyte, microglia (data not shown) or neuron cultures (Fig. 2D ) from either genotype did not induce apoptosis. When ~3000 p53 +/+ microglia were plated on top of p53 +/+ pure neuronal cultures, 200pM gp120 caused a significant increase in apoptotic neurons (Fig. 2 D) . In marked contrast, pure neuron cultures from p53 −/− mice were resistant to toxicity induced by gp120 treatment in the presence of p53 +/+ microglia (Fig. 2 D) , which suggests that at least some of the protection provided by p53 deficiency is intrinsic to neurons.
The microglial response to gp120 requires p53
To determine whether p53 −/− microglia create a neurotoxic milieu after gp120 exposure, cocultures of p53 +/+ neurons with p53 −/− or p53 +/+ microglia were exposed to gp120 and neuronal apoptosis assessed 24 h later. Only p53 +/+ microglia could transduce the neurotoxic signal from gp120 (Fig. 3A) . In fact, gp120-treated p53 −/− microglia caused a statistically significant decrease in the number of apoptotic neurons compared with control cultures, which suggests that, in the absence of p53, gp120 exposure may promote increased phagocytic activity that results in the removal of apoptotic neurons.
To begin to understand why p53 −/− microglia failed to mediate gp120-induced neurotoxicity, we first determined whether the signaling mechanisms leading to gp120-induced microglial activation are present in p53 −/− microglia. We observed no difference between p53 +/+ and p53 −/− microglia in their calcium response to ATP or thrombin (data not shown), which suggests that initial signal transduction pathways leading to microglial activation do not require p53 expression.
We hypothesized that one possible reason for an altered response to gp120 in p53 −/− microglia might be due altered surface expression of a gp120 receptor complex between CD4 and the appropriate chemokine receptor. The gp120 used in these experiments has been show to bind both CXCR4 and CCR5 chemokine receptors (29, 30) . Using flow cytometry of isolated primary microglia, we observed no significant difference in cell surface expression of CD4, CXCR4, and CCR5 between p53 +/+ and p53 −/− microglia (data not shown). Similar to findings reported for isolated human microglia (31), the cell surface expression level of these receptors was very low.
Positive control experiments on acutely isolated mouse splenocytes demonstrated that the antibodies recognized their appropriate antigens. Additionally, after acetone permeabilization, a much larger portion of cultured microglia (≈50%) contained CXCR4 immunoreactivity, which suggests that the culture conditions might prevent localization of the receptor to the plasma membrane.
To determine whether surface expression of these receptors depends on the context of attachment, p53 −/− and p53 +/+ microglia were plated on top of cultured wild-type neurons for 24 h, and cell surface expression of gp120 receptors was analyzed by live cell immuno-fluorescence microscopy. Co-cultures were labeled with rat monoclonal antibodies against murine CXCR4 and CCR5 for 30 min at 4°C to prevent phagocytosis of the antibodies, washed with several changes of cold media and secondarily labeled with Alexa594 conjugated anti-rat IgG. Images from 10 randomly selected fields were rapidly obtained on an inverted automated fluorescent microscope at room temperature. For each antibody, the background fluorescence intensity threshold was set at the 95th percentile of pixel intensity on co-cultures labeled with isotype control primary antibodies. The portion of microglia with fluorescence above background was determined after threshold segmentation of the digitized images. Although the subset of microglia with surface receptor expression for CXCR4 increased to near that observed after permeabilization of isolated microglia, there was no significant difference in the number of p53 −/− microglia with above background expression of CXCR4 (Fig. 3B) . However, cell surface expression of CCR5 (fluorescence intensity above isotype control) was detected in a significantly larger percentage of p53 −/− microglia (Fig. 3 B) .
We have previously reported that microglia undergo caspase-3 activation but do not progress to apoptosis following gp120 treatment (6, 32) . To determine whether p53 −/− microglia also demonstrate a similar partial activation of the apoptotic cascade following gp120 treatment, pure microglia cultures were treated with gp120 and assayed for caspase-3 activation 24 h later. Despite the presence of adequate gp120 receptors, p53 −/− microglia did not undergo increased caspase-3 activation after gp120 treatment (Fig. 3C ). Similar to our previously reported findings with rat microglia, both p53 +/+ and p53 −/− , microglia did not undergo apoptosis 24 or 48 h after treatment (Fig. 3D ). These findings demonstrate that p53 −/− microglia do not replicate the response to gp120 observed in wild-type microglia and suggest that caspase-3 enzymatic activity may participate in the process that leads microglia to release neurotoxic components into the surrounding media.
CNS HIV infection produces increased p53 protein in multiple cell types
To further investigate the possibility that p53 participates in HIV-induced neuropathology, cortical tissue sections obtained from the National NeuroAIDS Tissue Consortium (NNTC) or the University of Washington neuropathology specimen archives were immunohistochemically labeled for p53. Multiple previous studies have revealed minimal p53 immunoreactivity in control human brain, compared with the p53 protein accumulation in the nuclei of neurons in several neurodegenerative diseases (33-36). Therefore, we hypothesized that if p53 participates in HAD, then CNS tissue from patients with HAD would contain increased nuclear p53 immunoreactivity. Tissue obtained from patients with the premorbid diagnosis of HAD contained numerous cortical neurons and non-neuronal cells with strong nuclear immunoreactivity for p53, while p53 immunoreactivity comparable with that observed in HAD cases was rarely present in control tissue (Fig. 4A-D and Table 1 ). No immunoreactive nuclei were observed when the anti-p53 antibody was replaced with a control antibody of the same isotype or after the p53 antibody was pre-absorbed on fixed cells that had been infected with a human p53 expressing adenovirus. These control experiments prove that the antibody used to visualize p53 accumulation is a p53-specific antibody in this tissue immunolabel protocol.
To determine what specific non-neuronal cell populations demonstrate p53 activation in HAD cases, we double-labeled sections for p53 and the astrocyte-specific marker GFAP or the microglial marker CD68. Nuclear p53 accumulation was observed in a subpopulation of cells with GFAP-labeled cytoplasmic processes (Fig. 4E) , and a subpopulation of CD68-labeled microglia also develop nuclear p53 accumulation in HAD cases (Fig. 4F ). These findings suggest that HIV infection in the CNS is associated with nuclear accumulation of p53 protein in both neurons and non-neuronal cells.
Sections labeled for p53 immunoreactivity from 21 HAD cases and 18 control brains (7 HIV negative cases and 11 AIDS cases without HAD) were evaluated by at least two observers blinded to diagnosis (including one neuropathologist). The amount of p53 immunoreactivity present in neurons or non-neuronal nuclei in subcortical white matter was scored according to the following scale: 0 = no p53-labeled nuclei, 1 = <10% p53-labeled nuclei, 2 = 10-50% labeled nuclei and 3 = >50% labeled nuclei. Scoring discordance occurred in 12/78 observations and was resolved by the input of a third observer. This blinded analysis (Table 1) revealed that 71% of the HAD cases were identified as containing more than 10% p53 immunoreactive neurons (score of 2 or 3) and 57% were identified as demonstrating greater than 10% p53 immunoreactive nuclei in subcortical white matter. The frequency of cases containing greater than 10% p53-labeled nuclei was significantly higher in HAD cases than non-HAD controls for both neurons and nonneuronal cells. In an attempt to determine whether there was any evidence to suggest that p53 activation was observable in the cohort of AIDS patients that had not received a premorbid diagnosis of neurocognitive impairment, we evaluated the distribution of p53 scores in the three separate cohorts by ANOVA. This analysis (Fig. 5 ) revealed no statistically significant increase in mean p53 score in the AIDS without HAD cohort compared with the HIV-negative control group.
DISCUSSION
The findings reported here demonstrate that p53 protein accumulates in the nuclei of neurons and glia in patients with HAD. Evidence for activation of p53 in a wide variety of neurodegenerative diseases as well as acute CNS injury has been reported but the role of p53 in HAD has not been extensively studied. Accumulation of total p53 protein in the basal ganglia of monkeys with SIVE has been observed (15) , and the present study significantly expands on a recent report demonstrating activation of p53 in a small number of HAD cases (16) . These findings are especially relevant in the context of our observations that: 1) p53 −/− neurons are resistant to gp120 toxicity in co-culture with p53 +/+ microglia; 2) cultured primary microglia require p53 to transmit the toxicity of gp120 to neurons. The observation that p53 accumulates in multiple CNS cell types also suggests the pro-inflammatory environment associated with HAD may promote the expression of genes that lead to apoptosis in post-mitotic cells or cell cycle arrest in glia that might otherwise continue to proliferate.
Through the use of an in vitro model of HIV-induced neuronal injury, we report two potentially fundamental observations regarding the role of p53 in HAD. First, p53 is required for gp120-mediated neuronal apoptosis. Neurons from p53 −/− mice can undergo apoptosis in response to a variety of stimuli that activate p53-independent apoptotic pathways (37) (38) (39) (40) . Therefore, it is likely that the results presented here represent a true dependence on p53-mediated gene expression for gp120 induced neuronal apoptosis. This is perhaps not surprising in light of data demonstrating that gp120 toxicity is mediated in part by excitotoxins (1), and p53 −/− neurons are resistant to several models of excitotoxicity (17, 18, 41) . However, we previously reported that gp120 neurotoxicity requires activation of both a mitochondrial apoptotic pathway and a TNFα-caspase-8 dependent pathway in mixed cerebrocortical cultures (6) . Those studies could not distinguish whether TNFα acted directly on neurons or was involved in the gp120-mediated release of excitotoxins from microglia (42) or astrocytes (43) . Because caspase-8 dependent apoptosis would not necessarily involve p53-mediated gene expression, the hypothesis that neuronal p53 activation is necessary for gp120-induced neurotoxicity required experimental confirmation.
Results presented above definitively demonstrate that intrinsic neuronal p53 is required for gp120-mediated toxicity through the use of neuron/microglia co-cultures of mixed genotype.
Second, experiments described here demonstrate that p53 is also required for gp120-exposed microglia to create a neurotoxic milieu. When p53 −/− microglia were plated with p53 +/+ neurons, gp120 treatment did not yield increased neuronal apoptosis. The finding that microglia in microglia/neuron co-cultures require p53 to effectively transmit the toxicity of gp120 to neurons, in conjunction with the observation that gp120 exposure promotes caspase-3 activity in microglia (32) , suggests a possible link between the gene expression programs leading to apoptosis and microglial activation. Others have reported that activating stimuli lead to the up-regulation of pro-apoptotic genes in microglia. For example, microglia stimulated with lipopolysaccharide demonstrate increased expression of the cdk inhibitor p21 (WAF1) (44) , and microglial activation in the response to traumatic spinal cord injury is associated with induction of several genes in the p53-dependent apoptotic pathway (45) . Gene expression profile studies of peripheral dendritic cells, another cell type in the monocyte/macrophage lineage, demonstrate that many genes associated with apoptosis are induced after exposure to a variety of activating stimuli (46) . Finally, p53 expression enhances IL-6 mediated differentiation of a myeloblastic cell line into a macrophage phenotype (47) . Taken together with data presented here, these studies suggest that concomitant induction of apoptotic pathways may be required for microglial activation to ensue, perhaps as a means to ensure the eventual down-regulation of the immune response.
Further support for the hypothesis that microglial activation is linked with the induction of a p53-mediated apoptotic pathway comes from our observation that gp120-induced caspase-3 activation is absent in p53 −/− microglia. However, because microglia from both genotypes do not progress to apoptosis even 24 h after the increase in activated caspase-3 was observed, this finding could also support an alternative hypothesis: that caspase-3 activation somehow participates in the process of microglial activation and release of neurotoxins rather than to promote eventual microglial apoptosis. The concept that caspase enzymes participate in cellular processes other than apoptosis is not without precedent as caspases have demonstrated nonapoptotic rolls in lymphocyte function (48) and spermatogenesis (49, 50) .
We also observed that p53 deficiency was associated with increased microglia surface expression of CCR5. This finding was only observable in neuron microglia co-culture, as isolated microglia grown on an astrocyte feeder layer had nearly undetectable CCR5 and CXCR4 surface expression by flow cytometric methods. Further study is needed to determine whether surface chemokine receptor expression by microglia specifically requires contact with neurons or standard flow cytometric labeling procedures promote rapid receptor internalization by microglia. It was recently demonstrated that CCR5 activation can lead to increased p53 expression in breast carcinoma cells (51) , but the impact of p53 on CCR5 mRNA, protein or cell surface presentation has not been previously reported. The portion of both p53 +/+ and p53 −/− microglia with detectable surface expression of CCR5 was small, suggesting that this finding may not play an important role in the p53-dependent response to gp120. However, taken in conjunction with previous reports that the CCR5 ligands, β-chemokines, provide protection against HIV induced neurotoxicity (22), it is possible that even the small up-regulation of CCR5 surface expression on p53 −/− microglia in co-culture with neurons may contribute to the loss of a neurotoxic response to gp120. Previous studies demonstrate that both α-chemokines and CXCR4 preferring gp120 elicit independent neurotoxicity (22, 43) , suggesting that the gp120-CCR5 interaction may not promote neurotoxicity. Thus one possibility is that in the presence of p53 −/− microglia, gp120 is sequestered away from CXCR4 by a potentially higher binding affinity for CCR5 and/or the rapid internalization of bound CCR5 by microglia. A second hypothesis that may explain how a small increase in CCR5 surface expression on microglia could tilt the balance away from gp120-induced neurotoxicity, is that CCR5 stimulation might activate a distinct pathway in microglia, promoting release of soluble neurotrophic factors rather than neurotoxins. Studies are currently underway to determine the role of CCR5 surface expression in the microglial response to gp120. This in vitro model uses the toxicity elicited by exposure to HIV envelope protein.
Because previous studies demonstrated a role for p53 in the gp120 mediated toxicity observed in immune cells (12, 52, 53) and cell lines (12, 54) , we hypothesized that gp120 may also lead to p53 activation in CNS cells. It is also possible that other HIV proteins may modulate p53-mediated events. For example, induced expression of the HIV vpr gene also leads to p53 mediated cell cycle arrest and subsequent apoptosis (55) . Alternatively the HIV-1 nef protein appears to bind p53 and target it for degradation, thereby preventing p53-mediated apoptosis (56) . Nevertheless, because neurons, astrocytes, and the majority of activated microglia in HAD patients are not actually infected by HIV, p53 activation in bystander cells is most likely secondary to the effects of factors released into the extra-cellular environment. Thus, any down regulatory effect of nef expression would be limited to the sub-populations of microglia and macrophages actually infected with HIV. Finally, expression of an HIV tat sequence isolated from a patient with HAD can induce a monocytic cell line to secrete factors that result in p53 activation in human neuronal cell lines (16) . These reports, in conjunction with the data presented here, support the hypothesis that the widespread p53 activation observed in the majority of HAD cases may result from the convergence of toxic effects from multiple HIV proteins on one signaling pathway in multiple CNS cell types.
The data presented here support the model of HAD pathogenesis displayed in Fig. 6 . HIV migrates into the brain from infected circulating leukocytes and can establish productive infection in perivascular macrophages and a subset of parenchymal microglia. Infected cells secrete gp120 and other immunomodulatory factors that lead to activation of astrocytes and microglia. Accumulation of p53 protein in non-neuronal CNS cells ensues, leading to an altered microglia phenotype and release of additional factors that promote neurotoxicity. The function of p53 activation in astrocytes from HAD patients remains to be determined, but numerous possibilities exist, including altered chemokine receptor surface expression as seen in microglia. Eventually, the altered extracellular milieu produced by activated astrocytes and microglia will induce p53 activation in neurons, leading to synaptic and dendritic degradation and eventual apoptosis.
In summary, we have identified p53 activation as a novel component of the molecular phenotype of HAD. Surprisingly, findings reported here also revealed that p53-dependent signaling is required in both neurons and microglia for gp120 induced neuronal apoptosis. Taken together the results reported here justify further study of p53-dependent signaling in HAD, with the hope of identifying specific molecular targets for the prevention of neurodegeneration. from HAD patients. A) Cortical tissue from an HIV-negative patient labeled with an anti-p53 antibody reveals no p53 immunoreactivity. Scale Bar = 20 µm. B) Tissue from a HAD patient demonstrates numerous cortical neurons (arrows) with p53 immunoreactivity. Some cortical non-neuronal cells (arrowheads) were also p53-labeled. Scale Bar = 20 µm. C) Sub-cortical white matter from an HIV-negative patient labeled for p53 immunoreactivity did not contain evidence for nuclear p53 accumulation. Scale Bar = 20 µm. D) Tissue from a patient with HAD exhibits numerous p53 containing nuclei (arrowheads) in sub-cortical white matter. Scale Bar = 20 µm. E) Cortical tissue from a patient with HAD doublelabeled for GFAP (purple) and p53 (brown) reveals a subset of astrocytes with GFAP-labeled processes (arrows) that also contain nuclear p53 immunoreactivity. The cytoplasm surrounding other p53 labeled nuclei (arrowheads) are not immunoreactive for GFAP. Additionally, some GFAP-labeled astrocytes do not contain evidence for p53 accumulation (asterisk). Scale Bar = 20 µm. F) HAD cortical tissue double-labeled for the microglia marker CD68 (purple) and p53 (brown). Some microglia with CD68 labeled cytoplasm and processes (arrows) also demonstrate nuclear accumulation of p53 while other CD68 labeled microglia (asterisks) do not contain p53 immunoreactivity. Scale Bar = 30 µm. 6 . Schematic diagram. HIV enters the brain, productively infecting (blue arrows) perivascular macrophages, and microglia (green). Infected cells shed gp120 (solid black arrows) and potentially other factors that can cause p53 activation in astrocytes (blue) and microglia (green). Following p53 activation, microglia are induced to release factors (dashed arrows) that promote p53 activation and apoptosis in neurons (lavender).
